Organon & Co. Revenue
Organon & Co. (OGN) reported Revenue of $1.56 billion for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Income Statement
us-gaap:Revenues · last filed 2026-07-31
- Organon & Co. revenues for the quarter ending 2026-06-30 was $1.56B, a 2.26% decline year-over-year.
- Organon & Co. revenues for the quarter ending 2026-03-31 was $1.46B, a 3.50% decline year-over-year.
- Organon & Co. revenues for the quarter ending 2025-12-31 was $1.51B, a 5.34% decline year-over-year.
- Organon & Co. revenues for the quarter ending 2025-09-30 was $1.60B, a 1.26% increase year-over-year.
- Organon & Co. revenues for fiscal 2025 was $6.22B, a 2.92% decline from fiscal 2024.
- Organon & Co. revenues for fiscal 2024 was $6.40B, a 2.24% increase from fiscal 2023.
- Organon & Co. revenues for fiscal 2023 was $6.26B, a 1.44% increase from fiscal 2022.
- Organon & Co. revenues for fiscal 2022 was $6.17B, a 2.06% decline from fiscal 2021.
| Period end | Revenues 3 month | Revenues 6 month | Revenues 9 month | Revenues 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.56B 10-Q · filed 2026-07-31 | $3.02B 10-Q · filed 2026-07-31 | $4.53B derived: sum of 3 quarters · filed 2026-07-31 | $6.13B derived: sum of 4 quarters · filed 2026-07-31 |
| 2026-03-31 | $1.46B 10-Q · filed 2026-05-04 | $2.97B derived: sum of 2 quarters · filed 2026-05-04 | $4.57B derived: sum of 3 quarters · filed 2026-05-04 | $6.16B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-12-31 | $1.51B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.11B derived: sum of 2 quarters · filed 2026-02-24 | $4.70B derived: sum of 3 quarters · filed 2026-07-31 | $6.22B 10-K · filed 2026-02-24 |
| 2025-09-30 | $1.60B 10-Q · filed 2025-11-10 | $3.20B derived: sum of 2 quarters · filed 2026-07-31 | $4.71B 10-Q · filed 2025-11-10 | $6.30B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-06-30 | $1.59B 10-Q · filed 2026-07-31 | $3.11B 10-Q · filed 2026-07-31 | $4.70B derived: sum of 3 quarters · filed 2026-07-31 | $6.28B derived: sum of 4 quarters · filed 2026-07-31 |
| 2025-03-31 | $1.51B 10-Q · filed 2026-05-04 | $3.10B derived: sum of 2 quarters · filed 2026-05-04 | $4.69B derived: sum of 3 quarters · filed 2026-05-04 | $6.29B derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $1.59B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.17B derived: sum of 2 quarters · filed 2026-02-24 | $4.78B derived: sum of 3 quarters · filed 2026-02-24 | $6.40B 10-K · filed 2026-02-24 |
| 2024-09-30 | $1.58B 10-Q · filed 2025-11-10 | $3.19B derived: sum of 2 quarters · filed 2025-11-10 | $4.81B 10-Q · filed 2025-11-10 | $6.41B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | $1.61B 10-Q · filed 2025-08-06 | $3.23B 10-Q · filed 2025-08-06 | $4.83B derived: sum of 3 quarters · filed 2026-02-24 | $6.35B derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | $1.62B 10-Q · filed 2025-05-02 | $3.22B derived: sum of 2 quarters · filed 2026-02-24 | $4.74B derived: sum of 3 quarters · filed 2026-02-24 | $6.35B derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | $1.60B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $3.12B derived: sum of 2 quarters · filed 2026-02-24 | $4.72B derived: sum of 3 quarters · filed 2026-02-24 | $6.26B 10-K · filed 2026-02-24 |
| 2023-09-30 | $1.52B 10-Q · filed 2024-11-01 | $3.13B derived: sum of 2 quarters · filed 2024-11-01 | $4.67B 10-Q · filed 2024-11-01 | $6.15B derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-06-30 | $1.61B 10-Q · filed 2024-08-07 | $3.15B 10-Q · filed 2024-08-07 | $4.63B derived: sum of 3 quarters · filed 2025-11-10 | $6.17B derived: sum of 4 quarters · filed 2025-11-10 |
| 2023-03-31 | $1.54B 10-Q · filed 2024-05-03 | $3.02B derived: sum of 2 quarters · filed 2025-11-10 | $4.56B derived: sum of 3 quarters · filed 2025-11-10 | $6.14B derived: sum of 4 quarters · filed 2025-11-10 |
| 2022-12-31 | $1.49B derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | $3.02B derived: sum of 2 quarters · filed 2025-11-10 | $4.61B derived: sum of 3 quarters · filed 2025-11-10 | $6.17B 10-K/A · filed 2025-11-10 |
| 2022-09-30 | $1.54B 10-Q · filed 2023-11-03 | $3.12B derived: sum of 2 quarters · filed 2023-11-03 | $4.69B 10-Q · filed 2023-11-03 | $6.29B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $1.58B 10-Q · filed 2023-08-09 | $3.15B 10-Q · filed 2023-08-09 | $4.75B derived: sum of 3 quarters · filed 2024-02-26 | $6.36B derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $1.57B 10-Q · filed 2023-05-05 | $3.17B derived: sum of 2 quarters · filed 2024-02-26 | $4.77B derived: sum of 3 quarters · filed 2024-02-26 | $6.37B derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $1.60B derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $3.20B derived: sum of 2 quarters · filed 2024-02-26 | $4.80B derived: sum of 3 quarters · filed 2024-02-26 | $6.30B 10-K · filed 2024-02-26 |
| 2021-09-30 | $1.60B 10-Q · filed 2022-11-04 | $3.19B derived: sum of 2 quarters · filed 2022-11-04 | $4.70B 10-Q · filed 2022-11-04 | $6.31B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $1.59B 10-Q · filed 2022-08-05 | $3.10B 10-Q · filed 2022-08-05 | $4.71B derived: sum of 3 quarters · filed 2023-02-27 | $6.33B derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $1.51B 10-Q · filed 2022-05-06 | $3.12B derived: sum of 2 quarters · filed 2023-02-27 | $4.73B derived: sum of 3 quarters · filed 2023-02-27 | $6.26B derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $1.61B derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $3.23B derived: sum of 2 quarters · filed 2023-02-27 | $4.75B derived: sum of 3 quarters · filed 2023-02-27 | $6.53B 10-K · filed 2023-02-27 |
| 2020-09-30 | $1.61B 10-Q · filed 2021-11-12 | $3.14B derived: sum of 2 quarters · filed 2021-11-12 | $4.92B 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $1.53B 10-Q · filed 2021-08-16 | $3.31B 10-Q · filed 2021-08-16 | ||
| 2020-03-31 | $1.78B 10-Q · filed 2021-06-21 | |||
| 2019-12-31 | $7.78B 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |